# US 2006/0233820 A1 · Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0233820 A1
- Document ID: US20060233820A1
- Status: Published application
- Kind: A1
- Application number: 10/512,045
- Filed: 2003-04-04
- Published: 2006-10-19
- Earliest claimed: 2002-04-24
- Assignees: Neovacs
- Inventors: Daniel Zagury; Helene Le Buanec; Bernard Bizzini
- Web page: https://patentgrep.com/patent/US20060233820A1

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/53: {DNA (RNA) vaccination}
- C07K 2319/00: Fusion polypeptide
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in: i. the 1-19 amino acid sequence of sequence SEQ ID No. 3; ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and iii. the 30-98 amino acid sequence of sequence SEQ ID No.;

## Claims

### Claim 1

A vaccine composition lacking preventive or curative immunosuppressive property towards a cancer caused by a Papillomavirus infection, characterized in that it comprises, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in:
i. the 1-19 amino acid sequence of sequence SEQ ID No. 3;
ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and
iii. the 30-98 amino acid sequence of sequence SEQ ID No. 3, in association with one or more physiologically compatible immunity adjuvants.

### Claim 2 (depends on 1)

A vaccine composition according to claim 1, wherein the mutated E7 protein is characterized in that the amino acid region (ii) of said mutated E7 protein comprises at least two substitutions of amino acids, compared to the corresponding 20-29 peptide region of amino acids of sequence SEQ ID No. 3 of the native protein.

### Claim 3 (depends on 2)

A vaccine composition according to claim 2, wherein the mutated E7 protein is characterized in that the amino acid region (ii) of said mutated E7 protein comprises three, four, five, six, seven, eight, nine or ten substitutions of amino acids, compared to the corresponding 20-29 peptide region of amino acids of sequence SEQ ID No. 3 of the native protein.

### Claim 4 (depends on 2)

A vaccine composition according to claim 2, wherein the mutated E7 protein is characterized in that the Cys residues in position 24 and Glu in position 26 have been substituted by a distinct amino acid residue.

### Claim 5 (depends on 4)

A vaccine composition according to claim 4, wherein the mutated E7 protein is the (CYS24GLY, GLU26GLN) E7 protein.

### Claim 6 (depends on 4)

A vaccine composition according to claim 4, wherein the mutated E7 protein is the (CYS24SER, GLU26GLN) E7 protein.

### Claim 7 (depends on 1)

A vaccine composition according to claim 1, wherein the mutated E7 protein is characterized in that the amino acid region (ii) of said mutated E7 protein comprises the deletion of five, six, seven, eight, nine or ten consecutive amino acids, compared to the corresponding 20-29 amino acid sequence of SEQ ID No. 3.

### Claim 8 (depends on 7)

A vaccine composition according to claim 7, wherein the mutated E7 protein is characterized in that the amino acid region (ii) of said mutated E7 protein comprises the deletion of six consecutive amino acids, compared to the corresponding 20-29 amino acid sequence of SEQ ID No. 3.

### Claim 9 (depends on 8)

A vaccine composition according to claim 8, wherein the mutated E7 protein consists in the mutated E7 protein having the amino acid sequence comprising the deletion of the corresponding amino acids 21 to 26 of the SEQ ID No. 3 sequence of the native E7 protein.

### Claim 10 (depends on 7)

A vaccine composition according to claim 7, wherein the mutated E7 protein is characterized in that the amino acid region (ii) of said mutated E7 protein comprises the deletion of five consecutive amino acids, compared to the corresponding 20-29 amino acid sequence of SEQ ID No. 3.

### Claim 11 (depends on 10)

A vaccine composition according to claim 10, wherein the mutated E7 protein consists in the mutated E7 protein having the amino acid sequence comprising the deletion of the corresponding amino acids 21 to 25 of the SEQ ID No. 3 sequence of the native E7 protein.

### Claim 12 (depends on 1)

A vaccine composition according to claim 1, characterized in that it comprises at least one adjuvant able to preferably orient the immune response towards the production of antibodies neutralizing the immunosuppressive activity of the native E7 protein.

### Claim 13 (depends on 12)

A vaccine composition according to claim 12, characterized in that it comprises at least one adjuvant able to preferably orient the immune response towards the production of IgA isotype antibodies.

### Claim 14 (depends on 12)

A vaccine composition according to claim 12, characterized in that it comprises at least one adjuvant able to preferably orient the immune response towards the production of IgG isotype antibodies.

### Claim 15 (depends on 12)

A vaccine composition according to claim 12, characterized in that it comprises the combination (i) of one adjuvant able to preferably orient the immune response towards the production of IgA isotype antibodies and (ii) of one adjuvant able to preferably orient the immune response towards the production of IgG isotype antibodies.

### Claim 16 (depends on 15)

A vaccine composition according to claim 15, characterized in that it comprises at least one immunity adjuvant able to induce a humoral and cellular immune response.

### Claim 17 (depends on 7)

A vaccine composition according to claim 7, characterized in that the cellular response is characterized more particularly by the proliferation of lymphocytes expressing the CD8 antigen and specifically recognizing the wild E7 protein.

### Claim 18

An immunogenic composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in:
i. the 1-19 amino acid sequence of sequence SEQ ID No. 3;
ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and
iii. the 30-98 amino acid sequence of sequence SEQ ID No. °3,
in association with one or more physiologically compatible excipients or immunity adjuvants.

### Claim 19 (depends on 1)

A preventive or curative vaccine composition for a cancer caused by a HPV-16 infection, characterized in that it comprises an immunologically efficient amount of a nucleic acid encoding a mutated E7 protein, such as defined in claim 1, an expression cassette comprising said nucleic acid or a recombinant vector comprising said expression cassette.

### Claim 20 (depends on 1)

A use of a non immunosuppressive mutated E7 protein such as defined in claim 1, for preparing a non immunosuppressive immunogenic composition or a vaccine composition and which induces the production of an antibody neutralizing the immunosuppressive activity of the native E7 protein.

### Claim 21 (depends on 1)

Neutralizing antibodies directed against the expression product of the DNA encoding the mutated E7 protein such as defined according to claim 1.

### Claim 22 (depends on 21)

A composition for passive vaccination towards a HPV-16 infection containing antibodies according to claim 21.

### Claim 23 (depends on 1)

A vaccine composition lacking any preventive or curative immunosuppressive property towards a cancer caused by a Papillomavirus infection, characterized in that it comprises, as the active ingredient, an appropriate amount of autologous or allogenic dendritic cells towards the individual to be treated, said autologous dendritic cells having been incubated with a mutated E7 protein such as defined in claim 1 and thereby made able to present said mutated E7 protein to T cells.

### Claim 24 (depends on 1)

A method of preventing or treating some cancers associated with an infection through the HPV-16 type Papillovirus which comprises inoculating a subject prone to or afflicted with such a cancer with a vaccine composition according to claim 1.
